Posted by Michael Wonder on 08 Apr 2021
Wider storage and transportation conditions for the Pfizer COVID-19 vaccine now approved
8 April 2021 - The Therapeutic Goods Administration has recently approved wider storage and transportation conditions for the Pfizer COVID-19 vaccine in Australia (COMIRNATY - BNT162b2).
These changes will enable greater flexibility in storage, transport and deployment of the Pfizer COVID-19 vaccine across Australia.
While longer term storage at dry ice or ultra-cold temperatures (-90C to -60°C) is still required, for unopened vials, storage and transportation at domestic freezer temperatures (-25°C to -15°C) is now permitted for up to 2 weeks. Vials stored or transported in this manner can also be returned to ultra-cold longer term storage within the original shelf life of the product.
